Eli Lilly ( LLY 1.21%) and Novo Nordisk ( NVO 2.66%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.” He has suggested levies might be as high as 200%—part of his ...

Weight loss drugs, already a relatively new and revolutionary concept within the medical industry, are shaking things up once again. Move over Ozempic, pharmaceutical giant Eli Lilly […] ...